双示踪剂FDG与PSMA PET/CT定量参数对转移性激素敏感性前列腺癌进展为去势抵抗的预测价值
研究纳入45例接受新型激素治疗前行PSMA和FDG PET/CT的转移性激素敏感性前列腺癌患者,评估双示踪剂PET/CT定量参数对去势抵抗无生存期的预测价值。单因素分析仅前列腺癌MTV与CRPC-FS显著相关,40%阈值下PSMA和FDG的MTV预测力最强且多因素分析中保持独立。基于两参数构建的风险模型AUC>0.85。
要点
- FDG来源MTV较PSMA来源MTV对CRPC-FS预后价值更强。
- 40%阈值下PSMA和FDG的MTV为独立预测因子,切点分别为4.77和66.425。
- 双示踪剂PET/CT风险模型AUC>0.85,可辅助早期预后分层。
核心结论
- 在mHSPC患者中,MTV较其他PET/CT衍生参数和临床参数对CRPC-FS预后价值更优,且FDG来源MTV较PSMA来源MTV预后价值更强,双示踪剂模型有助于早期预后分层。
研究设计与样本
- 纳入2020年10月至2024年3月间45例于新型激素治疗前接受PSMA和FDG PET/CT的mHSPC患者,评估1661个PSMA阳性病灶和303个FDG阳性病灶,采用Cox回归和Kaplan-Meier分析,1000次bootstrap重采样内部验证,分类回归树确定最佳切点,时间依赖ROC评估模型区分度。
诊断标准与关键数值
- 单因素分析仅前列腺癌MTV与CRPC-FS显著相关(p<0.05);40%阈值下PSMA来源MTV的C-index为0.662,FDG来源MTV的C-index为0.712,二者切点分别为4.77和66.425;风险模型AUC>0.85。
临床应用与阅片要点
- 双示踪剂PET/CT定量参数(尤其40%阈值下FDG和PSMA的MTV)可用于mHSPC患者进展为去势抵抗的早期预后分层,辅助临床风险分组。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSES: To explore the prognostic value of dual-tracer PET/CT-derived parameters and develop a predictive model for castration-resistant prostate cancer-free survival (CRPC-FS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
METHODS: Forty-five mHSPC patients who underwent prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) PET/CT prior to novel hormone therapy (NHT) were included between October 2020 and March 2024. A total of 1,661 PSMA-positive and 303 FDG-positive lesions were evaluated to quantify tumor burden, including maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion uptake under different relative fixed threshold values. Cox regression and Kaplan-Meier analyses assessed their association with CRPC-FS. Internal validation was performed using 1000-bootstrap resampling. Classification and regression tree identified optimal cut-offs. Time-dependent receiver operating characteristic analysis evaluated model discrimination.
RESULTS: In univariate analysis, only MTV of prostate cancer was significantly associated with CRPC-FS (p < 0.05). PSMA-derived (C-index = 0.662) MTV and FDG-derived (C-index = 0.712) MTV under a 40 % threshold exhibited the strongest predictive power and remained independent in multivariable analysis. Internal validation demonstrated favorable model performance and good calibration. The cut-off values for the two parameters were identified as 4.77 and 66.425, respectively. Furthermore, patients were stratified into prognostic groups to develop a risk model with AUCs > 0.85.
CONCLUSIONS: MTV exhibited superior prognostic value for CRPC-FS in patients with mHSPC compared to other PET/CT-derived and clinical parameters. Moreover, FDG-derived MTV showed stronger prognostic value than PSMA-derived MTV. The dual-tracer PET/CT-derived model could comprehensively assess tumor burden and aid in early prognostic stratification.
引用
- Xiang F, Zeng Y, Zhang Z, et al. Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer. Eur J Radiol. 2025. PMID: 41421031. doi:10.1016/j.ejrad.2025.112614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。